138 related articles for article (PubMed ID: 7957889)
21. Long-term, genome-wide kinetic analysis of the effect of the circadian clock and transcription on the repair of cisplatin-DNA adducts in the mouse liver.
Yang Y; Liu Z; Selby CP; Sancar A
J Biol Chem; 2019 Aug; 294(32):11960-11968. PubMed ID: 31217280
[TBL] [Abstract][Full Text] [Related]
22. Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro.
Poirier MC; Lippard SJ; Zwelling LA; Ushay HM; Kerrigan D; Thill CC; Santella RM; Grunberger D; Yuspa SH
Proc Natl Acad Sci U S A; 1982 Nov; 79(21):6443-7. PubMed ID: 6959129
[TBL] [Abstract][Full Text] [Related]
23. Recognition and repair of DNA-cisplatin adducts.
Woźniak K; Błasiak J
Acta Biochim Pol; 2002; 49(3):583-96. PubMed ID: 12422229
[TBL] [Abstract][Full Text] [Related]
24. Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA.
Reed E; Gupta-Burt S; Litterst CL; Poirier MC
Carcinogenesis; 1990 Dec; 11(12):2117-21. PubMed ID: 1979937
[TBL] [Abstract][Full Text] [Related]
25. Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA.
Meczes EL; Azim-Araghi A; Ottley CJ; Pearson DG; Tilby MJ
Biochem Pharmacol; 2005 Dec; 70(12):1717-25. PubMed ID: 16259963
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of DNA-dependent protein kinase inhibition by cis-diamminedichloroplatinum(II)-damaged DNA.
Turchi JJ; Patrick SM; Henkels KM
Biochemistry; 1997 Jun; 36(24):7586-93. PubMed ID: 9200710
[TBL] [Abstract][Full Text] [Related]
27. Formation of cis-diamminedichloroplatinum(II) 1,2-intrastrand cross-links on DNA is flanking-sequence independent.
Burstyn JN; Heiger-Bernays WJ; Cohen SM; Lippard SJ
Nucleic Acids Res; 2000 Nov; 28(21):4237-43. PubMed ID: 11058123
[TBL] [Abstract][Full Text] [Related]
28. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease.
Huang JC; Zamble DB; Reardon JT; Lippard SJ; Sancar A
Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10394-8. PubMed ID: 7937961
[TBL] [Abstract][Full Text] [Related]
29. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells.
Li Q; Yu JJ; Mu C; Yunmbam MK; Slavsky D; Cross CL; Bostick-Bruton F; Reed E
Anticancer Res; 2000; 20(2A):645-52. PubMed ID: 10810335
[TBL] [Abstract][Full Text] [Related]
30. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor.
Zhai X; Beckmann H; Jantzen HM; Essigmann JM
Biochemistry; 1998 Nov; 37(46):16307-15. PubMed ID: 9819223
[TBL] [Abstract][Full Text] [Related]
31. DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA.
Sheibani N; Jennerwein MM; Eastman A
Biochemistry; 1989 Apr; 28(7):3120-4. PubMed ID: 2742829
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of excision repair of cisplatin-DNA adducts by cell-free extract from a cisplatin-resistant rat cell line.
Hibino Y; Hiraoka Y; Kamiuchi S; Kusashio E; Sugano N
Biochem Pharmacol; 1999 Jun; 57(12):1415-22. PubMed ID: 10353263
[TBL] [Abstract][Full Text] [Related]
33. Identification of inducible damage-recognition proteins that are overexpressed in HeLa cells resistant to cis-diamminedichloroplatinum (II).
Chao CC; Huang SL; Lee LY; Lin-Chao S
Biochem J; 1991 Aug; 277 ( Pt 3)(Pt 3):875-8. PubMed ID: 1872817
[TBL] [Abstract][Full Text] [Related]
34. DNA repair in human cells: quantitative assessment of bulky anti-BPDE-DNA adducts by non-competitive immunoassays.
Venkatachalam S; Denissenko M; Wani AA
Carcinogenesis; 1995 Sep; 16(9):2029-36. PubMed ID: 7554050
[TBL] [Abstract][Full Text] [Related]
35. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
Johnson SW; Swiggard PA; Handel LM; Brennan JM; Godwin AK; Ozols RF; Hamilton TC
Cancer Res; 1994 Nov; 54(22):5911-6. PubMed ID: 7954422
[TBL] [Abstract][Full Text] [Related]
36. DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts.
Kasparkova J; Novakova O; Farrell N; Brabec V
Biochemistry; 2003 Jan; 42(3):792-800. PubMed ID: 12534292
[TBL] [Abstract][Full Text] [Related]
37. The binding affinity of HMG1 protein to DNA modified by cis-platin and its analogs correlates with their antitumor activity.
Pasheva EA; Ugrinova I; Spassovska NC; Pashev IG
Int J Biochem Cell Biol; 2002 Jan; 34(1):87-92. PubMed ID: 11733188
[TBL] [Abstract][Full Text] [Related]
38. Conversion of DNA adducts of antitumour cis-diamminedichloroplatinum(II). Immunochemical analysis.
Vrána O; Kiseleva VI; Poverenny AM; Brabec V
Eur J Pharmacol; 1992 May; 226(1):5-13. PubMed ID: 1397055
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin adducts inhibit 1,N(6)-ethenoadenine repair by interacting with the human 3-methyladenine DNA glycosylase.
Kartalou M; Samson LD; Essigmann JM
Biochemistry; 2000 Jul; 39(27):8032-8. PubMed ID: 10891085
[TBL] [Abstract][Full Text] [Related]
40. Cisplatin-DNA damage recognition proteins in human tumour extracts.
Bissett D; McLaughlin K; Kelland LR; Brown R
Br J Cancer; 1993 Apr; 67(4):742-8. PubMed ID: 8471431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
